Positive data for Promedior’s PRM-151 boost development efforts in IPF

Idiopathic Pulmonary Fibrosis
GlobalData believes the new positive findings confirm Promedior’s PRM-151 potential as an alternative to the mechanisms of action adopted by the two therapies dominating the space.